We serve Chemical Name:2-[(2-Methylphenoxy)methyl]oxirane CAS:2210-79-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![2-[(2-Methylphenoxy)methyl]oxirane](https://a.dearchem.com/CAS2/2210-79-9.png)
Chemical Name:2-[(2-Methylphenoxy)methyl]oxirane
CAS.NO:2210-79-9
Synonyms:Epodil 742;o-Tolyl glycidyl ether;2,3-epoxy-1-(2-methylphenoxy)propane;glycidyl 2-methylphenyl ether;Heloxy 62;1-(2,3-epoxypropoxy)-2-methylbenzene;aralditedy023;o-Kresol-glycidaether;o-cresyl;O-CRESYL GLYCIDYL ETHER;MFCD00037847;o-Cresolglycidylether;DY 023;3-(2-methyl-phenyloxy)-1,2-epoxypropane;3-(2-methylphenoxy)-1,2-epoxypropane;[(2-methylphenoxy)methyl]oxirane;EINECS 218-645-3;1,2-epoxy-3-o-tolyloxypropane
Molecular Formula:C10H12O2
Molecular Weight:164.20100
HS Code:2910900090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:109-111ºC (4 mmHg)
Density:1.079
Index of Refraction:1.529
PSA:21.76000
Exact Mass:164.08400
LogP:1.77260
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3082
Packing Group:III
Contact us for information like Epodil 742 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2-epoxy-3-o-tolyloxypropane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00037847 Use and application,Heloxy 62 technical grade,usp/ep/jp grade.
Related News: The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1 Phenol, 4-[3-(ethoxydimethylsilyl)propyl]-2-methoxy- manufacturers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. N-phenyl-2-pyrrolidin-1-ylmethyl-benzamide suppliers The group of diseases known as severe combined immunodeficiency, or SCID, first drew wide attention decades ago because of David Vetter, a boy born with X-linked SCID who lived in a bubble for 12 years as doctors tried to figure out how to cure him. (4R,4aS)-4-(methoxymethoxy)-3,4,4a,5-tetrahydro-7H-oxazolo[3,4-b]pyridazin-7-one vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. N-phenyl-2-pyrrolidin-1-ylmethyl-benzamide suppliers The group of diseases known as severe combined immunodeficiency, or SCID, first drew wide attention decades ago because of David Vetter, a boy born with X-linked SCID who lived in a bubble for 12 years as doctors tried to figure out how to cure him. (4R,4aS)-4-(methoxymethoxy)-3,4,4a,5-tetrahydro-7H-oxazolo[3,4-b]pyridazin-7-one vendor & factory.
